Dynavax Technologies (NASDAQ:DVAX) Downgraded by StockNews.com

Dynavax Technologies (NASDAQ:DVAX – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other research firms also recently commented on DVAX. Zacks Investment Research downgraded Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 1st. TheStreet raised Dynavax Technologies from a “d+” rating to a “c” rating in a research report on Wednesday, March 30th. Finally, HC Wainwright initiated coverage on Dynavax Technologies in a research report on Wednesday, January 12th. They set a “buy” rating and a $28.00 target price on the stock. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Dynavax Technologies has a consensus rating of “Hold” and an average target price of $21.00.

Shares of NASDAQ DVAX traded up $0.48 during midday trading on Thursday, reaching $7.93. 2,584,027 shares of the company traded hands, compared to its average volume of 1,759,102. Dynavax Technologies has a 12 month low of $7.14 and a 12 month high of $21.39. The firm has a market cap of $1.00 billion, a PE ratio of 14.42 and a beta of 1.44. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.64 and a current ratio of 1.75. The stock’s 50-day simple moving average is $10.24 and its 200-day simple moving average is $13.03.

Dynavax Technologies (NASDAQ:DVAX – Get Rating) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.02). Dynavax Technologies had a net margin of 23.12% and a return on equity of 115.98%. During the same period in the prior year, the firm posted $0.01 earnings per share. On average, equities research analysts expect that Dynavax Technologies will post 1.23 EPS for the current year.

In other Dynavax Technologies news, CEO Ryan Spencer sold 83,108 shares of the business’s stock in a transaction that occurred on Thursday, March 3rd. The stock was sold at an average price of $10.56, for a total value of $877,620.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Justin Burgess sold 21,490 shares of the company’s stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $10.58, for a total value of $227,364.20. The disclosure for this sale can be found here. Insiders sold 170,496 shares of company stock valued at $1,801,527 over the last 90 days. 9.31% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of DVAX. Evoke Wealth LLC grew its position in shares of Dynavax Technologies by 3.8% in the third quarter. Evoke Wealth LLC now owns 35,904 shares of the biopharmaceutical company’s stock valued at $689,000 after purchasing an additional 1,300 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Dynavax Technologies by 0.4% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 369,953 shares of the biopharmaceutical company’s stock valued at $4,010,000 after acquiring an additional 1,413 shares during the period. Great Lakes Advisors LLC grew its stake in Dynavax Technologies by 7.6% in the 4th quarter. Great Lakes Advisors LLC now owns 21,695 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 1,527 shares during the period. Arizona State Retirement System lifted its holdings in Dynavax Technologies by 5.0% in the 1st quarter. Arizona State Retirement System now owns 32,425 shares of the biopharmaceutical company’s stock worth $351,000 after buying an additional 1,538 shares in the last quarter. Finally, Diversified Trust Co increased its stake in Dynavax Technologies by 7.4% in the 4th quarter. Diversified Trust Co now owns 22,418 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 1,539 shares during the period. 76.80% of the stock is owned by institutional investors.

About Dynavax Technologies (Get Rating)

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Featured Articles